Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256632 · ClinicalTrials.gov registry record · NA
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
A NA study of Choroidal Neovascularization, sponsored by Vision Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01256632: Completed NA study of Choroidal Neovascularization, sponsored by Vision Research Foundation.
NCT01256632 is a NA study of Choroidal Neovascularization that has completed, run by Vision Research Foundation. The registered enrollment target is 40 participants, below the 180-participant average among 7 other Choroidal Neovascularization trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01256632, a NA study of Choroidal Neovascularization, has completed, sponsored by Vision Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective: \*To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group. Secondary Objective: * To measure the mean change in visual acuity from Baseline to Month 12. * To measure the mean change in central retinal thickness per OCT from Baseline to Month 12
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Michigan
- Vision Research Foundation - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-10 |
| Phase | NA |
What the finished NCT01256632 record still lists
NCT01256632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 180-participant average among 7 other Choroidal Neovascularization trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Choroidal Neovascularization appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01256632 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01256632 about?
NCT01256632 is a clinical study titled "Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy". The primary objective: \*To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group. Secondary Objective: * To measure the mean change in visual acuity from Baselin...
What is the current status of trial NCT01256632?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2007-10. Estimated completion is 2010-10.
What conditions does trial NCT01256632 study?
This clinical trial studies the following conditions: Choroidal Neovascularization.
What interventions are being tested in trial NCT01256632?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01256632?
This trial is sponsored by Vision Research Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01256632 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
COMPLETED · Phase 1
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
COMPLETED · Phase 2
-
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia